Should I buy Amgen stock in 2025?

Why trust HelloSafe?

At HelloSafe, our expert has been monitoring Amgen’s performance for over three years. Every month, hundreds of thousands of users in the United States trust us to break down market trends and highlight the best investment opportunities. Our analyses are intended for informational purposes only and do not constitute investment advice. In line with our ethical charter, we have never been, and will never be, compensated by Amgen.

What is Amgen?

How much is Amgen stock?

The price of Amgen stock is declining this week. As of now, Amgen shares trade at $283.78, reflecting a 2.45% drop in the last 24 hours and a weekly decrease of 5.21%. The company holds a market capitalization of $152.57 billion and sees an average daily trading volume of 2.47 million shares over the past three months. Amgen’s P/E ratio stands at 25.85, with a healthy dividend yield of 3.35%, and the stock beta is 0.50, indicating relatively low volatility compared to the broader market. Investors should note the current dip in price may signal ongoing short-term volatility, providing potential opportunities for long-term positioning.

Our full analysis on Amgen stock

Over the past several quarters, our comprehensive evaluation of Amgen’s (NASDAQ: AMGN) latest financial disclosures and its three-year share price trajectory reveals a dynamic yet resilient biotechnology leader sharply positioned for renewed upside. By blending forward-looking financial ratios, robust technical signals, evolving market dynamics, and comparative peer analysis through our proprietary analytic algorithms, one central question emerges: Why might Amgen stock once again represent a strategic entry point into the biopharmaceutical sector as we move through 2025?

Recent Performance and Market Context

Despite short-term fluctuations, Amgen’s year-to-date performance (+8.88%) places it among the more consistently advancing stocks in the large-cap biotech universe, underpinned by its ability to deliver on financial guidance and capitalize on sector-wide tailwinds. After a temporary pullback to $283.78 (off the recent 52-week high of $346.85), Amgen’s one-year total return remains positive at 2.31%, even as many pharmaceutical peers have faced intensified market scrutiny.

Several recent events have injected optimism into Amgen’s narrative:

• Q1 2025 Results: Delivered robust revenue growth of 9% year-over-year, led by record product sales and impressive double-digit growth across multiple franchises.
• Dividend Strength: With a 3.35% yield and 13 consecutive years of dividend growth, Amgen presents a compelling dividend-growth profile, especially notable in a sector often associated with volatility rather than yield stability.
• Strategic M&A: The smooth integration of Horizon Therapeutics has strategically broadened Amgen's product offering, especially in autoimmune and rare disease portfolios.
• Supportive Macro Backdrop: Investors continue to favor healthcare and biotech as defensible, cash-generating sectors—particularly given persistent economic uncertainty and demographic-driven secular tailwinds.

These elements collectively support the case that Amgen stands out not just for its defensive qualities, but also for its renewed potential to outperform in the upcoming biopharma innovation cycle.

Technical Analysis

While recent market action signals short-term headwinds—with the stock currently trading below its major moving averages (20/50/100/200-day MAs)—several technical features point toward the possibility of a constructive reversal:

• Relative Strength Index (RSI): At 44.58, Amgen is neither oversold nor overbought, leaving ample room for a new upward move as investor sentiment shifts.
• MACD: With a minor negative differential (-4.66), Amgen shows classic signs of a potential base-formation period, where downside may be limited as buyers step in near cluster support zones.
• Support Levels: The $281-$282 region aligns with multi-month support—a level repeatedly defended in previous bottoms, historically attracting value-focused inflows.
• ADX (14): At a moderate 28.56, trend strength is adequate, suggesting resolution of the recent consolidation could yield decisive direction.

The present technical structure may thus resemble a late-stage correction within a larger bullish cycle, ultimately offering a lower-risk entry point for patient investors as fundamentals assert themselves in coming quarters.

Fundamental Analysis

Amgen’s latest quarter (Q1 2025) demonstrates the company’s enviable fundamental profile:

• Revenue and Earnings Growth: $8.1 billion in total revenue (+9% y/y) and non-GAAP EPS of $4.90 (+24% y/y) signal strong operational leverage and margin expansion.
• Valuation: Trading at a forward P/E of 13.59 and a PEG ratio below 1.0 (0.95), Amgen is valued attractively relative to projected growth—noteworthy in a sector where premium multiples often dominate. The price-to-sales ratio (4.59) and enterprise value/EBITDA (20.73) further position Amgen at a discount to its peer group, while maintaining above-average profitability.
• Dividend Profile: The payout ratio (83.23%) is sustainable given Amgen’s free cash flow generation and balance sheet maneuvering—with $1 billion in free cash flow and $2.8 billion in Q1 debt reduction, the company exhibits capacity to both reward shareholders and fuel innovation.
• Strategic Strengths: Multiple growth franchises (e.g., Repatha, EVENITY, Prolia, TEZSPIRE, and BLINCYTO) have each delivered double-digit gains, pointing to durable demand and adept lifecycle management. Amgen’s 14 franchises posting double-digit revenue growth also insulate it from revenue cliff risk.
• R&D and Pipeline: The late-stage pipeline is particularly promising, with advancements in cardiometabolic (MariTide, Olpasiran) and respiratory (TEZSPIRE) segments. International expansion and further market penetration for pipeline assets provide incremental upside.

Taken together, the current valuation appears unduly conservative in light of Amgen’s growth rate, cash flow, and expanding addressable markets—parameters likely to drive a rerating as uncertainties recede.

Volume and Liquidity

Amgen’s average 3-month trading volume of 2.47 million shares underscores its status as one of the NASDAQ’s most liquid, institutionally-trafficked biopharma names. High daily turnover enhances price discovery and offers an orderly entry/exit profile, supporting dynamic valuation and mitigating the risk of illiquidity-driven drawdowns. The company’s substantial market capitalization ($152.57 billion) and widely-held float further bolster its credentials as a blue-chip name within the global healthcare sector.

Catalysts and Positive Outlook

Looking forward, several catalysts are poised to drive Amgen’s next growth phase:

• Product Launches and Approvals: Continued momentum from blockbuster therapies (notably, TEZSPIRE and BLINCYTO) and well-regarded late-stage assets are primed for label expansions and new indications throughout 2025–2026.
• Horizon Acquisition Synergies: Full realization of integration benefits should support both top- and bottom-line progression, particularly as new therapies in autoimmune and rare diseases roll out on an international scale.
• Pipeline Progressions: Ongoing clinical trials for MariTide (obesity/diabetes), Olpasiran (cardiometabolic risk), and next-gen bispecifics support medium- to long-term narrative strength.
• ESG and Operational Excellence: Amgen’s commitment to sustainability, diversity, and responsible governance continues to attract ESG-sensitive institutional capital—an often underappreciated driver of valuation and liquidity.
• Sector Tailwinds: With demographic trends favoring increased demand for chronic disease therapeutics and an innovation-friendly U.S. regulatory landscape, Amgen’s business model is well-aligned with long-term industry growth drivers.

Consensus price targets ($313.39, or ~10% above current levels) reinforce analyst optimism regarding Amgen’s ability to convert these operational and pipeline strengths into sustainable shareholder value.

Investment Strategies

Given the confluence of technical support, improving fundamentals, and imminent catalysts, Amgen’s current trading range is conducive to both tactical and strategic entry strategies:

• Short-Term: The stock’s proximity to multi-month support around $281-$282, with clear resistance just above at $287–$292, may offer nimble investors favorable risk/reward for swing trades ahead of upcoming pipeline readouts and the dividend ex-date (May 16, 2025).
• Medium-Term: Investors looking for capital appreciation as well as total return can capitalize on Amgen’s historical pattern of post-earnings mean reversion and subsequent upside following periods of technical consolidation.
• Long-Term: For income-oriented and growth-focused portfolios, Amgen offers a rare combination of robust free cash flow, rising dividend distributions, and underappreciated pipeline value. The stock’s below-peer forward P/E and proven shareholder return strategy may appeal to those seeking core healthcare exposure with an attractive entry basis.

In the context of volatility, Amgen’s low beta (0.50) also supports portfolio diversification—particularly valuable in market environments characterized by macroeconomic uncertainty.

Is it the Right Time to Buy Amgen?

In sum, Amgen’s multifaceted strengths are difficult to overlook at current levels:

• Revenue and EPS growth are accelerating, underpinned by a diverse portfolio and transformative acquisitions.
• Technical support is strong, suggesting limited near-term downside and heightened potential for a reversal as momentum reemerges.
• Valuation multiples are notably attractive versus both sector and historical averages, with the growth outlook arguably underpriced by the market given imminent catalysts.
• Liquidity, dividend consistency, and a robust late-stage R&D pipeline collectively enhance the stock’s appeal to a broad spectrum of investors.

Against a backdrop of sector resilience, company-specific innovation, and favorable risk/reward, Amgen seems to represent an excellent opportunity for investors seeking both total return and defensive growth. The upcoming quarters appear rich with catalysts that could serve as inflection points. With a history of operational excellence and a solid foundation in both product and pipeline, Amgen’s current market positioning may warrant renewed attention from those pursuing the next phase of leadership within the biotechnology sector.

For discerning investors, Amgen’s combination of technical support, accelerating fundamentals, and imminent catalysts deserves close consideration as 2025 unfolds—a timeframe that could well see this industry heavyweight reclaim a position of outperformance and deliver measurable value at the intersection of yield and growth.

How to buy Amgen stock in United States?

Buying Amgen (AMGN) stock online is now simpler and safer than ever thanks to reputable, regulated brokerage platforms in the United States. Investors have two straightforward methods to gain exposure: purchasing shares outright (“spot buying”) or trading Contracts for Difference (CFDs). Each method has its own advantages—spot buying for long-term ownership and dividends, CFDs for flexibility and leverage. Whether you aim to invest for growth or short-term opportunities, there’s a method for you. To help you make the best choice, be sure to check out our detailed broker comparison further down the page.

Spot buying

A cash or spot purchase means you buy Amgen shares outright, becoming a direct shareholder and gaining the right to receive dividends. This is ideal if you want to hold shares long-term or benefit from Amgen’s consistent dividends—currently yielding around 3.35%. US brokers typically charge a fixed commission per order, usually between $0 and $6. In a typical scenario, with a brokerage fee of $5, here’s how a $1,000 investment works:

Example

If the Amgen share price is $283.78, you can acquire approximately 3 shares with a $1,000 stake, after accounting for a $5 brokerage fee (3 × $283.78 = $851.34, $1,000 - $851.34 = $148.66 remaining, insufficient for an additional share).

✔️ Gain scenario

If the share price rises by 10%, your shares would now be worth about $1,100.
Result: That’s a $100 gross gain, or +10% on your investment (excluding dividends).

Trading via CFD

CFD trading lets you speculate on Amgen’s price movement without owning the underlying shares, using leverage to amplify your market exposure. With CFDs, you pay the broker’s spread (the difference between buy and sell prices), and—if you hold overnight—a small financing charge. This method is popular among active traders aiming for short-term gains.

Example

You open a CFD position on Amgen with $1,000 and 5× leverage. This gives you $5,000 of market exposure.

✔️ Gain scenario

If Amgen’s stock rises by 8%, your position earns 8% × 5 = 40%.
Result: That’s a $400 profit on your $1,000 investment (before fees and financing costs).

Final advice

Before investing in Amgen, take time to compare broker fees, account types, and trading conditions via our broker comparison tool further down the page. Your ideal approach depends on your own investment goals—whether you prefer direct share ownership and dividends, or seek short-term trading opportunities with leverage. Whichever path you choose, understanding the different ways to buy Amgen stock is the first step towards confident investing.

Application

Rates & Fees

Learn More

#1

30+ million users

#1Recommended by Forbes

eToro

Rates & Fees

4.9

Discover

51% of CFD accounts lose money. You will never lose more than your investment.

#2

CFD and Indices Expert

#2

IG

Rates & Fees

4.9

Discover

74% of CFD accounts lose money. Your capital is at risk.

#3

CFD specialist

#3

Avatrade

Rates & Fees

4.8

On the broker's website

Our 7 tips for buying Amgen stock

The latest news about Amgen

Amgen delivered strong first-quarter 2025 results, posting 9% year-over-year revenue growth and 24% higher non-GAAP EPS. For Q1 2025, Amgen reported total revenue of $8.1 billion, up 9% from the prior year, and non-GAAP earnings per share rose sharply to $4.90, marking a 24% increase versus Q1 2024. These results were driven by robust double-digit growth from 14 major products, including standout performers like Repatha (up 27%), EVENITY (up 29%), Prolia (up 10%), and TEZSPIRE (up 65%). The company also improved its free cash flow by doubling it to $1 billion year-over-year, reflecting disciplined financial management and operational execution, which supports confidence in its U.S. business outlook.

Amgen maintains a consistent, growing dividend, reinforcing its appeal to income-focused U.S. investors. Amgen announced a forward annual dividend of $9.52 per share and the ex-dividend date is set for May 16, 2025, with payments to be made on June 6, 2025. The dividend yield stands at a competitive 3.35%, and the company has increased its dividend for 13 consecutive years. This ongoing commitment to shareholder returns, even amid sector volatility, underscores Amgen’s financial stability and continued value proposition for domestic investors seeking reliable income.

The company has taken decisive action to strengthen its balance sheet, reducing principal debt by $2.8 billion in Q1 2025. As of March 31, 2025, Amgen held $8.8 billion in cash and cash equivalents, providing solid liquidity. Management prioritized debt reduction, paying down $2.8 billion of principal debt in the first quarter of 2025, which helps alleviate concerns associated with leverage following major acquisitions. This move is particularly positive in the context of rising interest rates in the United States, as it reduces financial risk and demonstrates prudent stewardship.

Amgen’s product pipeline and integration of Horizon Therapeutics signal significant long-term growth potential in the U.S. market. The ongoing clinical progress for new treatments such as MariTide, Olpasiran, and TEZSPIRE, alongside the successful integration of Horizon Therapeutics, have meaningfully broadened Amgen’s portfolio in key therapeutic areas. These efforts support future product launches and provide new opportunities within the domestic healthcare space. Sustained investment in research and development is poised to keep Amgen competitive and relevant given evolving U.S. healthcare needs.

Despite short-term technical weakness, leading analyst consensus anticipates approximately 10% upside for Amgen stock. Although technical indicators currently suggest a bearish trend with the stock trading below all major moving averages and recent underperformance, analysts remain optimistic about Amgen’s fundamentals and future prospects. The consensus price target of $313.39 points to roughly 10% potential appreciation from current levels, highlighting continued confidence in the company’s earnings power, dividend reliability, and product momentum for investors in the United States.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.